News Mixed results for experimental Alzheimer's therapies at CTAD The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
News UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D UK start-up Oyster Therapeutics has raised $60m in first-round financing for its novel take on protein degraders, starting with tau in Alzheimer's.
News AbbVie's Cerevel takeover delivers Parkinson's approval The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.
News Iambic files IPO after signing up AbbVie as new partner In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.
News Reviews underway of first drug for rare disease MOGAD Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.
News Major trial of Roche Alzheimer's drug kicks off in Europe The PrevenTRON trial of Roche's Brainshuttle drug trontinemab in preclinical Alzheimer's disease has gotten underway in the UK.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.